Welcome to our dedicated page for HALBERD news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on HALBERD stock.
Halberd Corporation (OTC PINK:HALB) is a publicly traded company on the OTC Market, focusing on groundbreaking technologies and innovations. Recently, the company has been making strides in the field of Traumatic Brain Injury (TBI) mitigation and developing a patented LDN+ drug for active-duty military and veterans. The LDN+ drug is a combination of low-dose Naltrexone and Cyclobenzaprine, aimed at reducing anxiety, depression, addiction symptoms, PTSD, and Suicidal Ideation. Halberd Corporation's commitment to providing solutions for mental health issues facing military personnel underscores its dedication to making a positive impact on society.
Halberd Corporation (OTC PINK:HALB) announced animal testing of its patent-pending nasal spray at Mississippi State University to address the effects of Traumatic Brain Injury (TBI). This research follows successful in vitro results in collaboration with Youngstown State University and aims to mitigate TBI-related neurological complications such as PTSD. The triple-action nasal spray can be administered promptly post-injury to potentially reduce long-term damage. Funding for the animal testing program has been secured, with Dr. Russell Carr overseeing the research.
Halberd Corporation (OTC PINK:HALB) has partnered with Mississippi State University to conduct animal testing on novel therapies aimed at mitigating traumatic brain injury effects. The research will be led by the College of Veterinary Medicine and the Department of Biomedical Engineering at the university. Dr. Russell Carr expressed enthusiasm for the collaboration's potential outcomes. Halberd, since its restructuring in 2020, has secured exclusive rights to three patents and filed 22 related applications to enhance shareholder value. Further details regarding the testing scope and timeline are expected to follow.
Halberd Corporation (OTC PINK:HALB) made significant strides in the second half of 2022, including a 44.4% enhancement in COVID-19 antibody effectiveness and the establishment of Halberd Cancer Therapeutics, LTD. The company demonstrated control over PD-1, a key cancer protein, and formed strategic alliances to develop longevity treatments. Halberd's monoclonal antibody showed efficacy against antibiotic-resistant bacteria. The firm aims to restore compliance with SEC filing and is pursuing government contracts. Leadership focuses on R&D to secure future partnerships with Big Pharma.
Halberd Corporation (OTC PINK:HALB) has received antibiotic-resistant bacteria (ARB) strains from the CDC for testing its laser eradication technology. Previously reported successes on multiple Gram-Negative bacteria have paved the way for this new phase of testing. The CDC's collaboration emphasizes the potential military applications against bio-weapons. CEO William A. Hartman highlights the significance of this partnership for national safety and the company's interests. Halberd has made strides in intellectual property with multiple patents and pending applications.
Halberd Corporation has reported the successful application of its patented methodology for Cancer Antigen Eradication Treatment. CEO William Hartman and CTO Mitchell Felder discussed these groundbreaking achievements in an interview. The company's approach involves controlling cancer antigen levels, specifically CTLA-4, to enhance immune response without harmful side effects. This extracorporeal method aims to minimize drug-related fatalities, with over 100,000 deaths annually in the U.S. attributed to medication side effects. Halberd is progressing from in-vitro to in-vivo testing, seeking to advance its innovative treatment.
Halberd Corporation (OTC PINK:HALB) announced a peer-reviewed scientific article demonstrating its novel monoclonal antibody, which significantly boosts the effectiveness of an existing Covid antibody cocktail against the Omicron variant from 65% to over 94%. This achievement underscores the company’s innovative research capabilities. Halberd's antibody showcased effectiveness against all Covid-19 strains tested, indicating its potential for broad application in treating Covid-19. The article is set to be published soon, highlighting Halberd's ongoing commitment to advancing Covid-19 therapies.
Halberd Corporation has achieved significant success in laboratory tests, eradicating five key cancer disease antigens, including CTLA-4, using a patented process with laser emissive energy in under ten minutes. This innovative method aims to eliminate cancer-causing antigens from bodily fluids, potentially offering safer treatments with fewer side effects compared to conventional therapies. The company plans to target the BTLA antigen shortly. Halberd also emphasizes its commitment to reducing treatment costs and improving effectiveness through precise control of cancer antigens.
Halberd Corporation (OTC-PINK:HALB) has partnered with the newly formed Hamden Group, led by Darren Hamans and the Croden family, to enhance sales and distribution of its patented low-dose Naltrexone medication and Vita-Shield-Max™ nutraceutical product. The Hamden Group possesses extensive pharmaceutical experience, aiming to accelerate revenue for HALB. This contract grants Hamden exclusive rights worldwide for sales and marketing. CEO William Hartman notes the significant potential in sales for these products targeting various health conditions, including MS and addiction.
Halberd Corporation (OTC PINK:HALB) executives William A. Hartman and Dr. Mitchell S. Felder discussed transformative research milestones and their implications for healthcare during an interview on The Street Reports. They emphasized how their innovations could significantly impact the treatment of various diseases. Halberd, since its restructuring in 2020, has secured exclusive rights to three patents and has filed 22 additional patent applications to enhance stockholder value and attract development partners. For further updates, interested individuals can subscribe via the company's contact page.
FAQ
What is the current stock price of HALBERD (HALB)?
What is the market cap of HALBERD (HALB)?
What is Halberd Corporation focused on?
What is the LDN+ drug developed by Halberd Corporation?
What recent developments has Halberd Corporation made?
How is Halberd Corporation contributing to mental health solutions for military personnel?
